Healio (1/26, Weller) reports, “Depression rates were lower in patients treated with apremilast monotherapy for psoriasis or psoriatic arthritis [PsA] and higher in those treated with biologics, corticosteroids and non-apremilast combinations,” investigators concluded after analyzing “data from 67,189 patients (women, 43.9%; median age, 50.4 years) who had a diagnosis of psoriasis (77%) or psoriatic arthritis with or without psoriasis (23%) and at least one prescription claim for apremilast, conventional disease-modifying antirheumatic drugs (cDMARDs), biologics and/or systemic corticosteroids.” The findings were presented in a poster at the Maui Derm for Dermatologists meeting.
Related Links:
— “Depression rate lower with apremilast treatment for psoriasis, psoriatic arthritis “Madison Weller, Healio, January 26, 2021